| 1.02 0.073 (7.72%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.32 |
1-year : | 1.62 |
| Resists | First : | 1.13 |
Second : | 1.38 |
| Pivot price | 0.94 |
|||
| Supports | First : | 0.72 | Second : | 0.6 |
| MAs | MA(5) : | 1.03 |
MA(20) : | 0.95 |
| MA(100) : | 1.67 |
MA(250) : | 2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 52.5 |
D(3) : | 57.5 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 3.68 | Low : | 0.72 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GDTC ] has closed below upper band by 33.7%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.02 - 1.03 | 1.03 - 1.04 |
| Low: | 0.89 - 0.89 | 0.89 - 0.9 |
| Close: | 1.01 - 1.02 | 1.02 - 1.03 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Fri, 06 Feb 2026
CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - simplywall.st
Thu, 29 Jan 2026
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress - Yahoo Finance
Wed, 28 Jan 2026
CytoMed Therapeutics Refutes Misleading Claims, Confirms Ongoing First-in-Human Trial - TipRanks
Wed, 28 Jan 2026
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress - GlobeNewswire
Wed, 28 Jan 2026
CytoMed Therapeutics Addresses Inaccurate Claims About Its Research and Clinical Progress - Quiver Quantitative
Wed, 28 Jan 2026
Cancer cell therapy company hits back at claims about its first human trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 67.3 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | -452.2 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -42.4 % |
| Qtrly Rev. Growth | 101 % |
| Gross Profit (p.s.) | 0.05 |
| Sales Per Share | 0.06 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -4.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 16.39 |
| Price to Cash Flow | -3.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|